Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial - The Lancet

[unable to retrieve full-text content]

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial  The Lancet

Comments

Popular posts from this blog

8 Ways to Get Care When There Are No Primary Care Doctors - U.S. News & World Report

Vaccines Offer Protection Against Cold and Cough Symptoms - Pharmacy Times